Thus, the syndecan-4 mediated mechanotransduction pathway is likely to be broadly important in cancer, as the expression of syndecan-4 is high in cancers such as glioblastoma (117) and osteosarcoma (118), and the high expression correlates with reduced survival. Here, SDC4 is linked to osteosarcoma.